In vitro selection, via serial passage, of clostridium difficile mutants with reduced susceptibility to fidaxomicin or vancomycin

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 1, 2014, Pages 41-44

  Leeds, Jennifer A ^a   Sachdeva, Meena ^a   Mullin, Steve ^a   Whitney Barnes, S ^b   Ruzin, Alexey ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

Author keywords

LFF571; Marr; Murg; Rna polymerase

Indexed keywords

EXONUCLEASE; FIDAXOMICIN; GENOMIC DNA; N ACETYLGLUCOSAMINE; SERINE; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; CELL DENSITY; CLOSTRIDIUM DIFFICILE; GENE MUTATION; GENE SEQUENCE; IN VITRO SELECTION; IN VITRO STUDY; MOLECULAR CLONING; NONHUMAN; POINT MUTATION; VIRUS CULTURE;

LFF571; MARR; MURG; RNA POLYMERASE;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CELL WALL; CLOSTRIDIUM DIFFICILE; DNA MUTATIONAL ANALYSIS; DNA, BACTERIAL; DNA-DIRECTED RNA POLYMERASES; DRUG RESISTANCE, BACTERIAL; GENOME, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; SELECTION, GENETIC; SEQUENCE ANALYSIS, DNA; SERIAL PASSAGE; THIAZOLES; VANCOMYCIN;

EID: 84890413086     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt302     Document Type: Article

References (20)

1. Kelly CP, LaMont JT. Clostridium difficile in Adults: Treatment. http://www. uptodate.com/contents/clostridium-difficile-in-adults-treatment (2013) (11 May 2013, date last accessed).
2. Leeds JA, Sachdeva M, Mullin S et al. Mechanism of action of and mechanism of reduced susceptibility to the novel anti-Clostridium difficile compound LFF571. Antimicrob Agents Chemother 2012; 56: 4463-5.
3. Locher HH, PfaffP, Schroeder S et al. Cadazolid, a novel quinolonyloxazolidinone antibiotic with potent activity against Clostridium difficile: in vitro antibacterial activity and propensity for resistance development. In: Abstracts of the Fifty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA, 2012. Abstract C1-1346. American Society for Microbiology, Washington, DC, USA.
4. Seddon J, Sears P. Mutant prevention concentration of fidaxomicin for Clostridium difficile. In: Abstracts of the Fifty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA, 2012. Abstract C1-1274. American Society for Microbiology, Washington, DC, USA.
5. Babakhani F, GomezA, RobertNet al. Killing kinetics of fidaxomicinand its major metabolite, OP-1118, against Clostridium difficile. J Med Microbiol 2011; 60: 1213-7.
6. Clinical and Laboratory Standards Institute. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria-Seventh Edition: Approved Standard M11-A7. CLSI, Wayne, PA, USA, 2008.
7. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-second Informational Supplement M100-S22. CLSI, Wayne, PA, USA, 2012.
8. Clinical and Laboratory Standards Institute. Summary Minutes, Subcommittee on Antimicrobial Susceptibility Testing, Tempe, Arizona, January 2012. http://www.clsi.org/wp-content/uploads/2012/11/January- 2012.pdf (2012) (11 May 2013, date last accessed).
9. Li R, Li Y, Kristiansen K et al. SOAP: short oligonucleotide alignment program. Bioinformatics 2008; 24: 713-4.
10. Zerbino DR, Birney E. Velvet: algorithms for de novo short read assembly using de Bruijn graphs. Genome Res 2008; 18: 821-9.
11. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009; 25: 1754-60.
12. Li H, Handsaker B, WysokerAet al. The SequenceAlignment/Mapformat and SAMtools. Bioinformatics 2009; 25: 2078-9.
13. Alekshun MN, Levy SB. The mar regulon: multiple resistance to antibiotics and other toxic chemicals. Trends Microbiol 1999; 7: 410-3.
14. Goldstein EJ, Citron DM, Sears P et al. Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection. Antimicrob Agents Chemother 2011; 55: 5194-9.
15. Huang H, Weintraub A, Fang H et al. Antimicrobial resistance in Clostridium difficile. Int J Antimicrob Agents 2009; 34: 516-22.
16. HaS, Walker D, ShiYet al. The1.9A° crystal structureof EscherichiacoliMurG, a membrane-associated glycosyltransferase involved in peptidoglycan biosynthesis. Protein Sci 2000; 9: 1045-52.
17. Curry SR, MarshJW, Shutt KA et al. High frequencyof rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin Infect Dis 2009; 48: 425-9.
18. Friedman L, Alder JD, Silverman JA. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50: 2137-45.
19. StabbEV, HandelsmanJ. Genetic analysis of zwittermicinAresistance in Escherichia coli: effects on membrane potential and RNA polymerase. Mol Microbiol 1998; 27: 311-22.
20. Srivastava A, Talaue M, Liu S et al. New target for inhibition of bacterial RNA polymerase: 'switch region'. Curr Opin Microbiol 2011; 14: 532-43.